Aimei Health Technology Co., Ltd
NASDAQ:AFJKShell Companies
-$3.66 today
- Market cap
- $73.22M
- Beta
- 0.23
- P/E (TTM)
- 34.3
- EPS (TTM)
- $0.88
Volume 0.13M
Average 0.02M
AFJK Other Financing Activities
Financing cash flows not reported separately.
Aimei Health Technology Co., LtdNASDAQ: AFJK
Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026
Other financing activities dips below year-ago levels
Q1 FY2026 other financing activities of $158.86K fell 21.8% year over year, behind the +53.5% change in trailing-twelve-month other financing activities. Sequentially, it rose 267.9% from the prior quarter.
Context
- Other financing activities increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether quarterly growth recovers from -21.8% toward the trailing-twelve-month pace of +53.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- 539.82K USD
- Year-over-year change
- +350.7%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 539.82K | +350.7% |
| FY2024 | 2024-12-31 | 119.78K | — |
| FY2023 | 2023-12-31 | 0 | — |
Other Financing Activities vs competitors
How AFJK compares with its peers on the latest reported figures
- AFJK's LTM Mar 2026 other financing activities of $495.54K is the 7th largest of the 8 companies compared; the peer median is $45.56M.
- Its year-over-year change of +53.5% is the 3rd highest of 4, against a peer median of +69.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
KOYNCSLM Digital Asset Acquisition Corp III Class A Ordinary Shares | FY2025 | $233.88M | — | — | — |
| LTM Mar 2026 | $65.61M | — | — | — | |
UYSCUY Scuti Acquisition Corp. | LTM Dec 2025 | $56.41M | — | — | — |
| LTM Dec 2025 | $45.56M | +69.5% | +4.9% | 153.4% | |
EURKEureka Acquisition Corp Class A Ordinary Share | LTM Mar 2026 | $27.55M | -147.0% | — | — |
| LTM Mar 2026 | $15.85M | +12777.4% | — | — | |
AFJKAimei Health Technology Co., Ltd | LTM Mar 2026 | $495.54K | +53.5% | — | — |
ORIQUOrigin Investment Corp I Units | FY2025 | $48.25K | — | — | — |
| Peer median (excluding AFJK) | $45.56M | +69.5% | +4.9% | 153.4% | |
Competitors are the stored peer set for AFJK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | 171.39K | 2.55M | 1.06M |
| Depreciation & Amortization | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 |
| Change in Working Capital | 24.84K | 392.5K | 270.66K |
| Accounts Receivables | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 |
| Other Working Capital | 24.84K | 392.5K | 270.66K |
| Other Non-Cash Items | (196.23K) | (3.62M) | (1.9M) |
| Operating Cash Flow | 0 | (672.29K) | (565.1K) |
| Capital Expenditures | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | (69.69M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 |
| Other Investing Activities | 0 | (277.7K) | 63.58M |
| Investing Cash Flow | (69.69M) | (277.7K) | 63.58M |
| Debt Repayment | 0 | 277.7K | 1.75M |
| Common Stock Issued | 70.27M | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | (65.33M) |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | 0 | 119.78K | 539.82K |
| Financing Cash Flow | 70.27M | 397.48K | (63.04M) |
| Effect of Forex Changes | 0 | 0 | 0 |
| Net Change in Cash | 580.72K | (552.51K) | (25.28K) |
| Free Cash Flow | 0 | (672.29K) | (565.1K) |
Aimei Health Technology Co., Ltd
NASDAQ:AFJK
Intrinsic Alpha fair value
Locked
Current Price
$11.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.